Pure Global

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 - Trial NCT05684705

Access comprehensive clinical trial information for NCT05684705 through Pure Global AI's free database. This Phase 1 trial is sponsored by BioVersys AG and is currently Not yet recruiting. The study focuses on Bacterial Infections. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05684705
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05684705
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
A Single Center, Open-label Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 (Rifabutin for Infusion) in Healthy Participants

Study Focus

Bacterial Infections

BV100

Interventional

drug

Sponsor & Location

BioVersys AG

Vienna, Austria

Timeline & Enrollment

Phase 1

Mar 01, 2023

Dec 01, 2023

40 participants

Primary Outcome

To assess plasma concentration of rifabutin in healthy participants,To assess epithelial lining fluid concentration of rifabutin in healthy participants,To assess concentration of rifabutin in alveolar macrophages of healthy participants

Summary

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous
 Administrations of BV100

ICD-10 Classifications

Bacterial infection, unspecified
Bacterial, viral and other infectious agents
Other bacterial intestinal infections
Other bacterial diseases
Other specified bacterial intestinal infections

Data Source

ClinicalTrials.gov

NCT05684705

Non-Device Trial